To assess real-world adherence, persistence, switching, and reinitiation among US patients prescribed AJOVY.

AJOVY (fremanezumab), a fully-humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), has been approved for preventive treatment of migraine in adults.

Overall, 987 patients prescribed AJOVY were included; 594 (60.2%) had episodic migraine and 393 (39.8%) had chronic migraine. Most patients were female (842 [85.3%]) and 41-64 years of age (595 [60.3%]). Anxiety (152 [15.4%]) and depression (143 [14.5%]) were the most common comorbidities during the baseline period. Based on proportion of days covered of ≥80% and medication possession ratio of ≥80%, 738 (74.8%) and 780 (79.0%) patients, respectively, were adherent. 746 (75.6%) patients were persistent for ≥6 months. Of 216 (21.9%) patients who discontinued AJOVY, 7 (3.2%) switched to other CGRP pathway-targeted treatments (Emgality or Aimovig), 89 (41.2%) switched to a different acute or non-specific preventive treatment class, 21 (9.7%) reinitiated AJOVY treatment, and 103 (47.7%) permanently discontinued any acute or preventive migraine therapy.

Real-world treatment adherence and persistence were high with AJOVY; the majority of patients who discontinued AJOVY treatment discontinued any treatment or switched to a different preventive treatment class, and several patients restarted AJOVY.